1 DNA Way
South San Francisco
About Genentech, Inc.
Considered the founder of the industry, Genentech, now a member of the Roche Group, has been delivering on the promise of biotechnology for over 40 years. Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. We are among the world's leading biotech companies, with multiple products on the market and a promising development pipeline. Please take this opportunity to learn about Genentech where we believe that our employees are our most important asset & are dedicated to remaining a great place to work.
Connect with us!
Being a scientist at Genentech means being a drug discoverer. Mike Varney, head of Genentech Research and Early Development, explains how this culture of innovation is helping to solve some of the hardest biomedical problems of our time.
1417 articles with Genentech, Inc.
Roche’s Actemra failed to meet its primary and secondary endpoints in a late-stage study involving hospitalized patients with severe COVID-19 associated pneumonia.
The drug is an investigational monoclonal antibody being developed for tauopathies like progressive supranuclear palsy (PSP) and Alzheimer’s disease.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 29, 2020.
Phase III Data Show Port Delivery System With Ranibizumab Enabled Over 98% of Patients to Go Six Months Between Treatments for Neovascular Age-Related Macular Degeneration
In the Archway study, Port Delivery System with ranibizumab (PDS) demonstrated non-inferior and equivalent visual acuity outcomes compared with monthly ranibizumab eye injections, and a favorable benefit-risk profile PDS is a permanent refillable eye implant that continuously delivers a customized formulation of ranibizumab over a period of months, potentially reducing the treatment burden associated with frequent eye injections
7/20/2020It was a surprisingly big week for clinical trial updates related to COVID-19, although there was plenty of non-COVID-19 news as well. Here’s a look.
PicnicHealth Announces Strategic Partnership with Roche to Generate Scientific Insights from Real World Data
Real-world Datasets Will Be Used to Advance Research in Multiple Therapeutic Areas across Neurology, Hematology, and Rare Disease
Blueprint Medicines Announces Global Collaboration with Roche to Develop and Commercialize Pralsetinib for Patients with RET-Altered Cancers
Blueprint Medicines and Genentech, a member of the Roche Group, to co-commercialize pralsetinib and equally share profits in the U.S.
Shares of Blueprint Medicines are climbing in premarket trading after the company inked a collaboration worth more than $1 billion with Genentech to develop a treatment for cancers driven by oncogenic RET alteration.
New Data From Phase IIIb Study Reinforces Safety Profile of Genentech’s Hemlibra (emicizumab-kxwh) in People With Hemophilia A
Second interim analysis of the STASEY study, including data from 193 patients, consistent with results from Phase III HAVEN studies, with no new safety signals identified
Genentech Provides Update on Phase III Study of Tecentriq in Women With Advanced-stage Ovarian Cancer
Genentech, a member of the Roche Group, announced that the Phase III IMagyn050 study showed that the addition of Tecentriq® to Avastin®, paclitaxel and carboplatin did not meet its primary endpoint of progression-free survival for the front-line treatment of women with newly-diagnosed advanced-stage ovarian cancer.
Although the trial failed to meet the primary endpoint of PFS, the data for overall survival as a co-primary endpoint is not yet mature. The company plans to continue the trial until the next planned analysis.
Reverie Labs , a pharmaceutical company pioneering the application of artificial intelligence in the discovery and development of next-generation kinase inhibitors, today announced a multi-target collab
FDA Approves Genentech’s Phesgo (Fixed-dose Combination of Perjeta and Herceptin for Subcutaneous Injection) for HER2-positive Breast Cancer
Phesgo offers faster administration of Perjeta and Herceptin under the skin in just minutes, compared to hours with standard intravenous administration — — Data showed that 85% of patients preferred Phesgo compared to standard intravenous administration —
Genentech’s IPATential150 Study Evaluating Ipatasertib in Combination With Abiraterone and Prednisone/Prednisolone Met One of Its Co-Primary Endpoints
Phase III IPATential150 study evaluating ipatasertib in combination with abiraterone and prednisone/prednisolone compared to current standard-of-care (abiraterone and prednisone/prednisolone alone) plus placebo met its co-primary endpoint of radiographic progression-free survival (rPFS) in patients with PTEN loss tumors
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 19, 2020.
Genentech’s Tecentriq in Combination With Chemotherapy (including Abraxane) Meets Primary Endpoint of Improved Pathological Complete Response, Regardless of PD-L1 Status, as Initial Treatment for People With Early Triple-negative Breast Cancer
IMpassion031 data will be discussed with health authorities globally, including the U.S. Food and Drug Administration and the European Medicines Agency
In a Phase III study, Genentech’s Tecentriq (atezolizumab) in combination with Celgene’s Abraxane followed by chemotherapy demonstrated a statistically significant and clinically meaningful improvement in treating patients with early triple-negative breast cancer.
6/15/2020It was a fairly busy week with clinical trial updates and announcements. Here’s a look.
Positive Phase III Results for Venclexta Combination in Acute Myeloid Leukemia Presented At EHA 2020
Phase III VIALE-A study showed Venclexta plus azacitidine helped people with the most common type of aggressive adult leukemia live longer compared to azacitidine alone – – Data will be presented as a late-breaking abstract at the 25th European Hematology Association Virtual Congress –
Genentech Announces 2-Year Risdiplam Data From SUNFISH and New Data From JEWELFISH in Infants, Children and Adults With Spinal Muscular Atrophy (SMA)
SUNFISH Part 1 showed risdiplam significantly improved motor function after 24 months of treatment in people aged 2-25 years with Types 2 or 3 SMA – – JEWELFISH study preliminary 12-month data in previously treated patients showed rapid and sustained increases in SMN protein levels trial – – Safety was consistent with the safety profile observed to date and no new safety signals were identified – SOUTH SAN FRANCISCO, Calif.--( BUSINESS